HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS^® and TAGRISSO^® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Limited and AstraZeneca PLChave initiated SANOVO, a China Phase III study of ORPATHYS^®, an oral, potent, and highly selective MET tyrosine kinase inhibitor, in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (EGFR) TKI, TAGRISSO^® as a first-line treatment in certain non-small cell lung cancer patients whose tumors harbor EGFR mutation and overexpress MET.